Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL

Next Previous
X
Search
Trial Profile

RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms RIAltO

    • Most Recent Events

    • 12 Dec 2023 Results of deep immune profiling identifying novel T-Cell subpopulations that influence specific clinical outcomes in chronic lymphocytic leukaemia, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results assessing the immunomodulatory effects of chemo-immunotherapy plus idelalisib in chronic lymphocytic leukaemia patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 17 Jun 2018 Updated results of an ad hoc analysis (n=145) presented at the 23rd Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top